NASDAQ:SCNX 16 October 2025 - 24 October 2025

Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the company announced Arbli™ was available through major wholesalers – making it the first FDA-approved liquid losartan on the market ts2.tech. That morning, SCNX shares surged over 30% from the prior day’s $0.72 close, even hitting an intraday high around $1.12 before profit-taking set in ts2.tech. By mid-day Oct. 16, Reuters reported the stock had pulled back near $0.71 ts2.tech, indicating traders sold into the early pop. Still, the news established a new baseline of investor optimism. After a brief consolidation, momentum picked up again on Oct. 22. Despite no fresh news that day, SCNX spiked +10.9% intraday on unusually heavy volume Ainvest. Market analysts pointed out that no obvious technical sell signals were present, so the sudden move looked like a technical breakout or short-covering rally rather than a fundamentally driven jump Ainvest Ainvest. In other words, traders appeared to be positioning ahead of an anticipated announcement – a hint of the “buy the rumor” dynamic often seen in speculative stocks.

Pills and a daily pill organizer: Arbli’s liquid formulation helps patients who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwideglobenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to nearly 95 cents” on the newsragingbull.com. By mid-day, Reuters reported SCNX trading near $0.71, up ~30% from the prior closereuters.com. President Narasimhan Mani highlighted that the launch “opens access to a meaningful new patient segment” and “not only [drives] near-term revenue growth, but also validates our strategy to bring innovative, patient-focused formulations to multiple therapeutic categories”globenewswire.com. Similarly, Executive Chairman Shankar Hariharan called the rollout “a paradigm shift… by making Arbli™ available through major wholesalers, ensuring pharmacies and providers can immediately access this breakthrough therapy”globenewswire.com. These statements emphasize how Scienture is converting its FDA approval into real sales.